These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29275856)

  • 21. European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study.
    Dollfus S; Mucci A; Giordano GM; Bitter I; Austin SF; Delouche C; Erfurth A; Fleischhacker WW; Movina L; Glenthøj B; Gütter K; Hofer A; Hubenak J; Kaiser S; Libiger J; Melle I; Nielsen MØ; Papsuev O; Rybakowski JK; Sachs G; Üçok A; Brando F; Wojciak P; Galderisi S
    Front Psychiatry; 2022; 13():826465. PubMed ID: 35173641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.
    Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
    Schizophr Bull; 2018 Feb; 44(2):453-462. PubMed ID: 28575321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia.
    Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
    Acta Psychiatr Scand; 2018 Nov; 138(5):420-431. PubMed ID: 30168131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bridge centrality network structure of negative symptoms in people with schizophrenia.
    Wang LL; Tam MHW; Ho KKY; Hung KSY; Wong JOY; Lui SSY; Chan RCK
    Eur Arch Psychiatry Clin Neurosci; 2023 Apr; 273(3):589-600. PubMed ID: 35972557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Issues in selection of instruments to measure negative symptoms.
    Daniel DG
    Schizophr Res; 2013 Nov; 150(2-3):343-5. PubMed ID: 23899996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study.
    Kane JM; Yang R; Youakim JM
    Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale.
    Strauss GP; Keller WR; Buchanan RW; Gold JM; Fischer BA; McMahon RP; Catalano LT; Culbreth AJ; Carpenter WT; Kirkpatrick B
    Schizophr Res; 2012 Dec; 142(1-3):88-92. PubMed ID: 23127378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.
    Hopkins SC; Ogirala A; Loebel A; Koblan KS
    Schizophr Bull; 2018 Apr; 44(3):593-602. PubMed ID: 28981857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The brief negative symptom scale: validation of the German translation and convergent validity with self-rated anhedonia and observer-rated apathy.
    Bischof M; Obermann C; Hartmann MN; Hager OM; Kirschner M; Kluge A; Strauss GP; Kaiser S
    BMC Psychiatry; 2016 Nov; 16(1):415. PubMed ID: 27876020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time will tell: Associations between unbalanced time perspectives and symptom severity in individuals with schizophrenia spectrum disorders.
    Damiani S; Zarbo C; Stolarski M; Zamparini M; Casiraghi L; Rocchetti M; Starace F; Fusar-Poli P; de Girolamo G;
    Schizophr Res; 2023 Nov; 261():116-124. PubMed ID: 37717509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The brief negative symptom scale: psychometric properties.
    Kirkpatrick B; Strauss GP; Nguyen L; Fischer BA; Daniel DG; Cienfuegos A; Marder SR
    Schizophr Bull; 2011 Mar; 37(2):300-5. PubMed ID: 20558531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of primary negative symptoms in schizophrenia: an one-year observational study.
    Franza F; Fasano V; De Guglielmo S; Solomita B
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S245-9. PubMed ID: 26417773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial.
    Kashani L; Shams N; Moazen-Zadeh E; Karkhaneh-Yousefi MA; Sadighi G; Khodaie-Ardakani MR; Rezaei F; Rahiminejad F; Akhondzadeh S
    J Psychiatr Res; 2017 Nov; 94():70-77. PubMed ID: 28688338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revisiting the latent structure of negative symptoms in schizophrenia: Evidence from two second-generation clinical assessments.
    Li SB; Liu C; Zhang JB; Wang LL; Hu HX; Chu MY; Wang Y; Lv QY; Lui SSY; Cheung EFC; Yi ZH; Chan RCK
    Schizophr Res; 2022 Oct; 248():131-139. PubMed ID: 36037646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study.
    Zoccali R; Muscatello MR; Cedro C; Neri P; La Torre D; Spina E; Di Rosa AE; Meduri M
    Int Clin Psychopharmacol; 2004 Mar; 19(2):71-6. PubMed ID: 15076014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.